KIT and renal cell carcinoma: Famitinib (6) (5-[2-(diethylamino)ethyl]-2-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-3-methyl-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4-one) is a TKI that binds VEGFRs 2 and 3, PDGFR, FLT-1 and FLT-3, and the stem cell factor receptor (c-KIT and SCFR) and is involved in the dysregulation of several solid tumors, such as renal cell carcinoma and nasopharyngeal cancer [63,64].